We have code-named this new division, the Longwood Bulls.
To harness the scientific
analysis skills and expertise of PhDs to
deconstruct complex high tech companies and their competitive
landscapes. Our goal is to gain experience and build a network within
the startups and investments world, but also in a fun way through our
scientific lens. We
will build our reputation by regularly posting articles online as a
team, and by organizing networking events around Harvard Medical School.
Help each other learn about high-tech investments by:
1. Learning together the technical skills/knowledge we need to analyze financials.
2. Identifying good investment opportunities and analyzing them together as a team.
3. Networking through engagements and by organizing events together as a team.
Click to see the portfolio of articles we have published as a team on Seeking Alpha !
Managing Director: Shyh-Chang
Co-Directors: Alex Guth, Derek DiRocco
Analysts: Brian DuBoff, Eun-Jin Yang, Qinghui Yu, Luhan Yang, David Yang, Thomas Schaus
Derek is a postdoctoral fellow at Harvard Medical School and currently works in Dr. Benjamin Humphreys’ lab. His research is centered on determining novel genetic and molecular drivers that may underlie the progression of chronic kidney disease and acute kidney injury. Derek was awarded a postdoctoral research fellowship from the National Kidney Foundation for his proposed work on the role of the Wnt signaling pathway in kidney fibrosis. In addition to his research, Derek has strong interests in learning about (1) strategies used to successfully develop and commercialize therapeutics (2) best practices for growing new companies through venture capital investments and (3) fundamental analysis of publicly traded biopharma companies for investment purposes. Derek was previously a graduate student in the department of pharmacology at the University of Washington where he was awarded a Ruth L. Kirschstein predoctoral research fellowship.
Qinghui is currently pursing research on molecular and cellular mechanisms of cognitive function and cognitive disorders. Qinghui did her doctoral research at Columbia University, where she worked on understanding how developmental monoamine signaling impacts adult neuropsychiatric disorders. She joined the Longwood Bulls to explore her interests in translating scientific research in the labs into commercial products.
I'm a 5th year graduate student in Dr. Andrew McMahon's lab studying molecular biology and developmental genetics using next-generation sequencing techniques. My research interest is to apply ChIP-seq and RNA-seq in studying the gene regulatory networks in mouse embryonic stem cells and in spinal cord embryonic development. Besides experimental work, I have also been trained in statistics and bioinformatics; in particular, applying statistical methods and software on genome-wide data analysis. Right now, I'm finishing my thesis at the Biostatistics and Computational Biology Department at Harvard Medical School. After graduation, I am interested in doing strategy consulting, with an emphasis on quantitative analysis and analytics. In my leisure time, I like eating, traveling, talking and idling!
David is a first year postdoctoral fellow at Dana-Farber Cancer Institute/Harvard Medical School in Dr. Rosalind Segal’s lab. His current project examines the microenvironment of pediatric brain tumors – the most common form of solid tumors in children. Using primary human tumor cells in novel, ex-vivo assays, he is assessing the role of the tumor microenvironment in the development of this pediatric cancer. Novel, targeted therapeutic options may be developed by targeting the tumor-microenvironment interaction. This project is part of a large-scale P01 program grant, currently one of two programs in the country funded by NIH targeting this childhood disease. David is also awarded a T32 Ruth L. Kirschstein postdoctoral research fellowship by Boston Children’s Hospital. David has a strong interest in pursuing a career in intellectual property and technology commercialization, and is registered to practice before the USPTO as a patent agent.